Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

作者：Xiangyu Gao, Nong Xu, Ziyu Li, Lin Shen, Ke Ji, Zhong Zheng, Dan Liu, Hanmei Lou, Li Bai, Tianshu Liu, Yunxia Li, Yuzhi Li, Qingxia Fan, Feng Mei, Haijun Zhong, Yi Huang, Ge Lou, Jing Wang, Xiaoyan Lin, Ye Chen, Ruifang An, Changzheng Li, Qi Zhou, Xin Huang, Zengqing Guo, Shubin Wang, Guiling Li, Junwei Fei, Lijing Zhu, Hong Zhu, Xiu-Min Li, Fenghu Li, Sihai Liao, Qinghua Min, Lei Tang, Fei Shan, Jifang Gong, Yunong Gao, Jun Zhou, Zhihao Lü, Xiaofan Li, Jianjie Li, Hui Ren, Xiaohong Liu, Hongxia Yang, Wenting Li, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Xiaohua Wu, Jiafu Ji · 发表于：The Lancet Oncology · 年份：2023 · DOI：10.1016/s1470-2045(23)00411-4 · 被引用次数：206 · 研究领域：Cancer Immunotherapy and Biomarkers、CAR-T cell therapy research、Peptidase Inhibition and Analysis